Stratos Wealth Partners’s InMed Pharmaceuticals INM Stock Holding History

Stratos Wealth Partners’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.7K	Buy	+10,760	New	+$11.9K	﹤0.01%	1686

Other funds holding INM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Stratos Wealth Partners's INM Position: Q2 2026 in Review

Stratos Wealth Partners opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 10,760 shares worth $16.7K. The stake represents ﹤0.01% of the portfolio and ranks #1686 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

Stratos Wealth Partners held 10,760 shares of InMed Pharmaceuticals worth $16.7K as of Q2 2026.
InMed Pharmaceuticals was a new Stratos Wealth Partners position in Q2 2026.
InMed Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1686 holding.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.